Get the Daily Brief
Latest Biotech News
10x, Roche, Prognosys sue Illumina — patents hit spatial, single‑cell tech
10x Genomics joined Roche Sequencing Solutions and Prognosys Biosciences to file two federal lawsuits accusing Illumina of infringing nine patents tied to spatial biology and single‑cell...
Alector’s dementia drug fails Phase III: company halves staff and slumps
Alector reported a negative Phase III readout for its dementia candidate latozinemab, partnered with GSK, prompting a sharp stock drop and plans to cut roughly half of its workforce. The study...
Takeda, Innovent ink $11.4bn I‑O, ADC pact — $1.2bn up front
Takeda and China’s Innovent struck a sweeping oncology collaboration that could reshape both companies’ cancer pipelines. Takeda agreed to jointly develop and commercialize up to three...
Moderna CMV miss: pivotal Phase III fails — program largely halted
Moderna reported that its mRNA‑1647 cytomegalovirus (CMV) vaccine missed the primary efficacy endpoint in a large Phase III trial and will stop most development of the program. The company said...
FDA clears Blenrep return — mixed authorization for multiple myeloma
The FDA granted a constrained approval for GSK’s BCMA‑targeting ADC Blenrep, allowing its use in patients with relapsed or refractory multiple myeloma after at least two prior lines of therapy and...
Deep learning accelerates antibiotic discovery — two Nature Biotech reports
A pair of Nature Biotechnology papers demonstrate that deep‑learning models trained on high‑throughput phenotypic and screening datasets can identify novel antibacterial scaffolds. One study...
Live embryo imaging finds late mitotic errors — PGT‑A accuracy questioned
UK researchers using light‑sheet microscopy published long‑duration live imaging of late‑stage human preimplantation embryos and observed de novo chromosome segregation errors in trophectoderm...
Base editors hit the clinic: 23 programs now running — early activity seen
BioCentury reports that 23 base‑editor therapeutics have entered clinical development, with over half producing initial readouts that consistently show clinical activity. The tally spans in vivo...
Ventyx NLRP3 inhibitor posts striking Phase II biomarker drops — partner chatter
Ventyx Biosciences reported Phase II data for oral NLRP3 inhibitor VTX‑3232 showing rapid, large reductions in inflammatory biomarkers. The company said VTX‑3232 monotherapy cut hsCRP by roughly...
10x, Roche and Prognosys sue Illumina — spatial and single‑cell patents at issue
10x Genomics, joined by Roche Sequencing Solutions and Prognosys Biosciences, filed twin lawsuits accusing Illumina of infringing nine patents tied to spatial transcriptomics and single‑cell...
Alector’s Phase III flop triggers program halt and staff cuts
Alector disclosed that a GSK‑partnered antibody failed its Phase III dementia study, prompting the company to stop development of that asset and cut roughly half its workforce. The failure follows...
FDA accepts IND supported solely by organoid efficacy — regulators shift
Qureator announced that the FDA approved an IND amendment for SillaJen’s combination therapy based solely on human vascularized organoid (vTIME) efficacy data — the first U.S. IND relying on...
Takeda buys global rights to Innovent’s oncology assets — $1.2bn upfront
Takeda signed a licensing and collaboration agreement with China’s Innovent Biologics to secure global rights outside Greater China to two late-stage oncology programs, committing $1.2 billion...
FDA grants limited return for GSK’s Blenrep — split approval narrows label
The U.S. Food and Drug Administration cleared GSK’s BCMA-targeting antibody–drug conjugate Blenrep for use in multiple myeloma under a narrowed approval: the agency authorized Blenrep in...
Moderna halts CMV vaccine program after Phase III failure — pivot to oncology
Moderna announced that its mRNA cytomegalovirus vaccine mRNA‑1647 failed to meet the primary efficacy endpoint in a large Phase III pivotal trial and will largely stop further development of the...
Base editors see 23 clinical programs — early readouts point to activity
Industry trackers report 23 distinct base‑editing programs have entered the clinic, with more than half producing initial clinical readouts showing consistent signals of activity. The landscape...
Ventyx’s oral NLRP3 inhibitor cuts inflammation biomarkers — investors take notice
Ventyx Biosciences reported Phase II data for oral NLRP3 inhibitor VTX‑3232 showing rapid, large reductions in high‑sensitivity C‑reactive protein (hsCRP) and other cardiovascular inflammation...
10x, Roche and Prognosys sue Illumina over spatial and single‑cell patents
10x Genomics teamed with Roche Sequencing Solutions and Prognosys Biosciences to file two federal lawsuits accusing Illumina of infringing nine patents tied to spatial biology and single‑cell...
Cellarity publishes AI‑driven cell‑state discovery framework in Science
Cellarity reported a new framework in Science describing how integrated transcriptomics and AI models can identify compounds that correct pathological cell states. The paper lays out a systematic...
Retrons repurposed for precise genome editing — new tools emerge
Researchers unveiled retron‑based gene‑editing platforms that use bacterial reverse transcriptases to synthesize donor single‑stranded DNA intracellularly, enabling precise insertion and editing...